DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneSMAvoice.com | ||
If you'd like to unsubscribe and stop receiving these emails click here |
Trusted Resources: News & Meetings
Latest announcements and gatherings
Biogen Exercises Option With Ionis to Develop and Commercialize Investigational ASO for SMA
Biogen, Inc. and Ionis Pharmaceuticals, Inc. announced that Biogen exercised its option to obtain from Ionis a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306. The companies have a broad strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs of patients as well as to be administered at extended dosing intervals. Biogen plans to advance BIIB115 to clinical trials to investigate safety, tolerability, pharmacokinetics, and efficacy.
“Combining Biogen’s expertise in neurology with Ionis’ leadership in antisense technology has led to SPINRAZA® (nusinersen) being a foundation of care in SMA,” said Toby Ferguson, M.D., Ph.D., Vice President and Head of the Neuromuscular Development Unit at Biogen.


Related Content
-
News & MeetingsBiogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMABiogen announced it intends to initiate ...
-
EducationSpinal Muscular Atrophy Patient iPSC-Derived Motor Neurons Display Altered Proteomes at Early Stages of Differentiat...Spinal muscular atrophy (SMA) is an auto...
-
News & MeetingsNew Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
-
EducationComparative All-Cause Mortality Among a Large Population of Patients With Spinal Muscular Atrophy Versus Matched Con...Introduction: There is little informatio...
-
News & MeetingsFDA Lifts Partial Clinical Hold on Novartis’ SMA Drug ProgrammeThe US Food and Drug Administration (FDA...
-
News & MeetingsScholar Rock Provides Corporate Update and Highlights Priorities for 2022Scholar Rock, a clinical-stage biopharma...
-
People & PlacesKaren S. Chen, PhDKaren Chen is the Chief Executive Office...
send a message
Reset password
password changed successfully!

please log in with your email address and new password.
your activation key expired
this confirmation key has expired. please try to log in again or resend confirmation email.
confirmation email sent

a confirmation email has been sent to your inbox. click the link in the email to activate your account.
can't find the email? be sure to check your spam folder.
password reset email sent

an email has been sent to you with a link to reset your password.
can't find the email? be sure to check your spam folder.

If you are a doctor or other qualified health care professional, you should not offer any medical advice or treatment on our Sites, nor should you allow the content of our Sites to substitute for your own medical judgment. Please thoroughly review the information provided on our Sites before deciding whether any of the products, services, or treatments therein are right for you or others.
your account is now activated!

Log in
You need to log in to use this feature.
you haven't confirmed your email address yet. resend confirmation email